Norway, Aug. 18 -- PCI Biotech Holding ASA announces the discontinuation of development of the photochemical lysis (PCL) technology for viral vector manufacturing. Today's decision is primarily based on the insufficient progress towards the 2025 goal of demonstrating improved yield in mini benchtop bioreactors. Achieving successful end-to-end results in small bioreactors is a critical risk- reducing milestone for further development.Following the progress reported in the preliminary 2024 Interim Report (27(th) Feb 2025) and the Annual Report 2024 (24(th) April 2025), additional initiatives were undertaken to demonstrate PCL's capability to increase net AAV yield in an end-to-end process. However, efforts to date have not yielded convincing ...